

# PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
**CIOLINA ET AL.**

Examiner: SITA, P.

Art Unit: 1636

Application No.: 09/646,399

Filed: **NOVEMBER 1, 2000**

Title: **NUCLEIC ACID TRANSFER  
VECTORS, COMPOSITIONS  
CONTAINING SAME AND USES**

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
Regular Mail in an envelope addressed to  
Commissioner for Patents, Washington, D.C. 20231, on

Date of Deposit **12 August 2002**

Signature 

### STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE COPIES PURSUANT TO 37 C.F.R. 1.821 (f)


Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

  
William C. Coppola, Reg. No. 41,686

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-4854  
Telefax (908) 231-2626

Aventis Docket No. ST98008A